Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.65 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.64 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.64 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078023 | 0.93 | CCR3 (0.57) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL6102617 | 0.89 | CCR3 (0.56) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL15247841 | 0.81 | CYP19A1 (0.49) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL7247560 | 0.81 | ALDH1A1 (0.61) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL31549530 | 0.81 | CARM1 (0.75) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL11209800 | 0.81 | MAOA (0.59) | CCR3CARM1PRMT6 | |
| SCHEMBL674276 | 0.80 | GBA1 (0.71) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL2027845 | 0.80 | GBA1 (0.71) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL19101456 | 0.80 | CCR3 (0.65) | CCR3CARM1PRMT6PRMT3PRMT1 | |
| SCHEMBL13884225 | 0.80 | CCR3 (0.65) | CCR3CARM1PRMT6PRMT3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| EP-1268478-B1 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARM INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7199117-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-7087757-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-7041827-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-7041828-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001074814-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5981520-A | USEFUL FOR TREATING ASTHMA, BRONCHOSPASM, ALLERGIES, ANXIETY, COUGHING OR PAIN | SCHERING CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0042570-B1 | 20-DEOXYROSARAMICIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1983-10-19 | — | — | EP | disclosed |
| EP-0042570-A1 | 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4279896-A | Novel 20-imino macrolide antibacterial agents | SCHERING CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | GAP43, NLN, TRPV1 | CCR3 2573/4885CARM1 4768/4885PRMT6 3812/4885 |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | TPH2, TPH1, IDO2 | CCR3 2595/4885CARM1 1411/4885PRMT6 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.